A year ago, the drug-eluting punctual plug technology created by incubator ForSight Labs LLC didn’t exist. Today, the drug-eluting technology might make or break publicly traded QLT Inc.
The eye care company—reeling from several setbacks including Genentech Inc.’s release of ranibizumab ( Lucentis), a rival drug to QLT’s verteporfin (Visudyne), is betting big on the Newco II, the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?